MedTrace Logo

D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia

NCT00237848 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2012-06-18

No results posted yet for this study

Summary

This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia.

Conditions

Interventions

DRUG

D-serine

BEHAVIORAL

Cognitive retraining

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Donaghue Foundation

    collaborator UNKNOWN

  • US Department of Veterans Affairs

    collaborator FED

  • VA Office of Research and Development

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Deepak C. D'Souza, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00237848 on ClinicalTrials.gov